Media headlines about Calithera Biosciences (NASDAQ:CALA) have trended somewhat positive on Thursday, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Calithera Biosciences earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:

Insider Buying and Selling by Quarter for Calithera Biosciences (NASDAQ:CALA)

Calithera Biosciences (NASDAQ CALA) opened at 15.35 on Thursday. The company’s market capitalization is $541.76 million. Calithera Biosciences has a one year low of $2.20 and a one year high of $17.70. The firm has a 50-day moving average of $14.25 and a 200 day moving average of $9.71.

Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.14. The firm had revenue of $4.19 million for the quarter, compared to analysts’ expectations of $1.40 million. Equities research analysts predict that Calithera Biosciences will post ($0.85) earnings per share for the current fiscal year.

CALA has been the subject of a number of research reports. Zacks Investment Research raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Thursday, March 30th. Leerink Swann reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Calithera Biosciences in a research note on Monday, April 3rd. Wells Fargo & Company reissued an “outperform” rating and set a $20.00 price target (up previously from $15.00) on shares of Calithera Biosciences in a research report on Tuesday, June 6th. HC Wainwright reissued a “buy” rating and set a $14.00 price target (up previously from $10.00) on shares of Calithera Biosciences in a research report on Tuesday, March 28th. Finally, JMP Securities reissued an “outperform” rating and set a $12.00 price target on shares of Calithera Biosciences in a research report on Tuesday, March 28th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $14.17.

TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Receive News & Stock Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related stocks with our FREE daily email newsletter.